[Skip to Content]
[Skip to Content Landing]
Article
December 1986

Deferoxamine Improves Left Ventricular Function in ß-Thalassemia

Author Affiliations

From the Departments of Cardiology (Mr Grisaru and Drs Gotsman and Hasin) and Hematology (Drs Goldfarb and Rachmilewitz), Hadassah Hospital and the Hebrew University, Jerusalem.

Arch Intern Med. 1986;146(12):2344-2349. doi:10.1001/archinte.1986.00360240058011
Abstract

• Serial echocardiographic examinations were made to study the changes in left ventricular (LV) function and wall mass in 35 patients with thalassemia followed up for 5.5 ±2 years (mean ± SD). Twenty patients received deferoxamine sulfate for 2.0 ±0.6 years (drug group) and 15 patients did not (nondrug group). Repeated blood transfusions were used to maintain the pretransfusion hemoglobin levels at 9 g/dL (90 g/L). Deferoxamine therapy improved LV function and decreased LV wall mass. Percentage shortening of LV diameter improved in the drug group (5.0%±3.9%) and deteriorated in the nondrug group (-6.8%±5.6%). Similarly, the maximum velocity of LV posterior wall motion improved in the drug group (16.1± 20.1 mm/s) and deteriorated in the nondrug group (-18.3 ±19.0 mm/s). Left ventricular wall mass decreased in the drug group when compared with the nondrug group. In a subset of the drug group, pathologic natural deterioration in LV systolic function was

×